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Genetics of PICALM Expression and Alzheimer’s Disease
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Abstract
Novel Alzheimer’s disease (AD) risk factors have been identified by genome-wide association studies. Elucidating the
mechanism underlying these factors is critical to the validation process and, by identifying rate-limiting steps in AD risk, may
yield novel therapeutic targets. Here, we evaluated the association between the AD-associated polymorphism rs3851179
near PICALM, which encodes a clathrin-coated pit accessory protein. Immunostaining established that PICALM is expressed
predominately in microvessels in human brain. Consistent with this finding, PICALM mRNA expression correlated with
expression of the endothelial genes vWF and CD31. Additionally, we found that PICALM expression was modestly increased
with the rs3851179A AD-protective allele. Analysis of PICALM isoforms found several isoforms lacking exons encoding
elements previously identified as critical to PICALM function. Increased expression of the common isoform lacking exon 13
was also associated with the rs3851179A protective allele; this association was not apparent when this isoform was
compared with total PICALM expression, indicating that the SNP is associated with total PICALM expression and not this
isoform per se. Interestingly, PICALM lacking exons 2–4 was not associated with rs3851179 but was associated with
rs592297, which is located in exon 5. Thus, our primary findings are that multiple PICALM isoforms are expressed in the
human brain, that PICALM is robustly expressed in microvessels, and that expression of total PICALM is modestly correlated
with the AD-associated SNP rs3851179. We interpret these results as suggesting that increased PICALM expression in the
microvasculature may reduce AD risk.
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Introduction
Alzheimer’s disease (AD) is a devastating disease marked by
cognition and memory decline, affecting the elderly population.
Twin and family-based studies suggest that sporadic late onset AD
risk is genetically linked [1,2]. Recent genome wide association
studies (GWAS) have identified loci of genetic variance, single
nucleotide polymorphisms (SNP)s, that are associated with AD risk
[3–10]. Elucidating the mechanism of action of these SNPs
validates the SNP as an AD risk factor and may identify novel AD
pathways. Additionally, since steps in AD pathways that are
modulated by genetics may be susceptible to pharmacologic
manipulation, identifying the actions of AD-associated SNPs may
lead to robust new pharmacologic targets.
One of these SNPs is near the gene PICALM (phosphatidylino-
sitol binding clathrin assembly protein) which is involved in
endocytosis. The primary AD-associated SNP is rs3851179 [9–
11], which lies approximately 80 kb 59 of PICALM. PICALM itself
is encoded by 21 exons, several of which are variably spliced [12].
Here, we sought to elucidate how rs3851179 alters PICALM
expression or splicing to modulate AD risk. We report that
PICALM is expressed robustly in microvessels and moderately in
other cell types. Rs3851179 was modestly associated with total
PICALM expression as well as the major PICALM isoform lacking
exon 13. In contrast, the expression of rare PICALM isoforms
lacking exons 2, 2–4, or 18–19 was not associated with rs3851179.
We interpret our results as suggesting that the PICALM is robustly
expressed in microvessels and that the protective rs3851179A
allele is associated with modestly increased PICALM expression.
We speculate that increased microvessel PICALM reduces AD risk,
perhaps by facilitating Ab clearance from the brain through
enhanced translocation across the blood brain barrier.
Materials and Methods
Ethics Statement
The work described here was performed with approval from the
University of Kentucky Institutional Review Board.
Tissue samples
The RNA and DNA samples for this study were from de-
identified AD and non-AD autopsy samples. Anterior cingulate
specimens were provided by the University of Kentucky AD Center
Neuropathology Core and have been described previously [13,14].
A total of 52 brain samples, 28 male and 24 female, were used for
this study. All of the non-AD individuals were cognitively intact at
their last visit (MMSE of 27.963.4 (mean 6 SD)). AD individuals
were demented (MMSE of 12.268.3). For the AD autopsy
samples, the average age at death and postmortem interval was
82.966.4 years (mean 6 SD) and 3.460.7 hrs, respectively. For
the non-AD samples, the average age at death and postmortem
interval was 82.368.7 years (mean 6 SD) and 2.860.8 hrs,
respectively. By NIARI neuropathology criteria, the non-AD
individuals included 21 samples with a score of no-low likelihood
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of AD, and 6 with intermediate. The AD samples were uniformly
high-likelihood of AD. RNA was prepared by the method of
Chomczynski and Sacchi [15] and converted to cDNA with
random hexamers and Superscript II, as described previously [13].
Although RNA integrity analyses were not performed prior to
reverse transcription, others have demonstrated that for qPCR
with short amplicons, normalized expression differences are
comparable between samples with moderate RNA degradation
and those with high integrity RNA [16].
PICALM immunostaining
Paraffin-embedded anterior cingulate tissue sections (5 mm
thick) were rehydrated, underwent heat-induced antigen retrieval
in citrate buffer (pH 6.0) and were quenched in 0.3% H2O2.
Sections were immersed in 10% rabbit serum in Tris-buffered
saline followed by an overnight incubation in anti-CALM (sc-
6433, Santa-Cruz; 1:400 dilution). After thorough rinsing in Tris-
buffered saline, sections were incubated in biotinylated secondary
antibody for 1 h, rinsed, incubated in ABC reagent (Vector) for
1 h, developed in Nova Red chromagen (Vector) and counter-
stained with Hematoxylin.
Identification of PICALM Splice Variants in Human Brain
Screening for PICALM splice variants was performed on a pool
of cDNA samples from five AD and five non-AD individuals. This
cDNA pool was amplified by PCR by using forward and reverse
primers designed to produce overlapping products; this enabled
evaluation of splicing efficiency of each internal exon (Table 1).
The identity of splice variants was determined by sequencing. To
estimate the distribution of these splice variants, exon 12–20 PCR
products from three rs3851179 homozygous minor (A/A) and
three homozygous major (G/G) individuals were TA-cloned
(Invitrogen) and 847 random clones were sequenced. For this
work, thirty cycles of PCR (Platinum Taq, Invitrogen) were
performed by using primers corresponding to exons 12 and 20
(Table 1). PCR conditions were 94u for 15 seconds, 60u for 15
seconds, and 72u for 60 seconds (Veriti 96-Well Thermal Cycler,
Life Tech). PCR was conducted using approximately 30 ng of
cDNA template. After PCR, samples were cloned into pcDNA2.1
according to the manufacturer’s instructions (TA-Cloning Kit,
Invitrogen) and sequenced.
Quantitation of PICALM Expression
Total PICALM expression was quantified by qPCR using
primers corresponding to sequences within the constitutively
present exons 9 and 10 (Table 1); PICALM isoforms lacking exon
2, exons 2–4, 13 or 18–19 were quantified similarly (Table 1). As
no single Ensembl transcript incorporates each of the exons that
we identify here, note that our exon designations are derived from
ENST00000393346 for exons 1–16. Exons 17–21 correspond to
the final five exons within ENST00000532317. PCR was
conducted using an initial 2-minute incubation at 95u, followed
by cycles of 10 seconds at 95u, 20 seconds at 60u, and 20 seconds at
72u. The 20 mL reactions contained 1 mM of each primer, 1x
PerfeCTa SYBR Green Super Mix (Quanta Biosciences), and
30 ng cDNA. Experimental samples were amplified in parallel
with serially diluted standards that were generated by PCR of
cDNA using the indicated primers followed by purification and
quantitation by UV absorbance. Results from samples were
compared relative to the standard curve to calculate copy number
in each sample. Real time assays were performed at least twice and
the average copy number used for data analyses. Since PICALM
was expressed in microvessels, neurons and astrocytes, we wished
to compare PICALM expression to that of genes specific to these
cell types. Hence, we also quantified two microvessel-specific
mRNAs, CD31 and von Willebrand Factor (vWF), neuron-specific
mRNA SYP and astrocyte-specific GFAP. [17,18]. The copy
number for each mRNA was then normalized to the geometric
mean of reference genes RPL32 and EIF4H, previously quantified
in this sample set [13,14]. The linear regression statistical model
used to analyze the data included the geometric mean of CD31
and vWF (microvessel mRNA), GFAP, SYP, AD status and the
number of rs3851179 minor alleles (SPSS version 21).
Results
To begin to evaluate the role of PICALM in AD, we localized
PICALM expression in human brain by performing immunohis-
tochemistry. We used an antibody that recognizes an epitope at
the extreme PICALM carboxyl terminus that is found in all
PICALM isoforms (see below). Robust PICALM expression was
observed in microvessels in both non-AD and AD brain sections
(Figure 1). Consistent with other reports, we also observed less
robust PICALM immunostaining in other cell types that have
been identified as neurons and glia [19,20].
Table 1. PCR Primers.
Target Name Sequence (59-39)
Exons 1–5 1F Sense CTGACGGACCGAATCACTG
5R Antisense TCAAGAAGTGCATCCATCTGA
Exons 3–9 3F Sense TGGCTTCAAGAAACACGTTG
9R Antisense GCTTGCAGCTGTAGAATCTTTG
Exons 7–12 7F Sense TGAAAAAGAACCAATGCAAAGA
12R Antisense CCCCATGTACTTGCTACCTGA
Exons 10–14 10F Sense CTTTCCAATGCAGTGTCTTCC
14R Antisense CCCCAGAATCTACTACAATAACATTTG
Exons 12–17 12F Sense GCCCAATGATCTGCTTGATT
17R Antisense CATTGTTGCAGCATTCCAAG
Exons 15–20 15F Sense GCTTTGATGAACTAGGTGGACTT
20R Antisense GCAGTTTGGATTTTGCTGGA
Total PICALM 9 Sense ACAGGCCCCTAGCAGTCTTC
10 Antisense TGCTTTTCCCTTTCATCCAC
D13 11 Sense TGCAGCCTCTCCTGTATCCACCT
12–14
Junction
Antisense GGAGAAGGAGTGAATCCTCCC
D18–19 17 Sense TGGAGTCAACCAGGTGAAAA
17–20
Junction
Antisense CATTTGTGGAGGCATTGTTG
D2 1 Sense GAGGAGCTGCAGAGATGTCC
1–3 Junction Antisense TACTGAATAAAACGAGTCCAGGTG
D2–4 1–5 Junction Sense AAAGCACCTGGACTGGCTGA
6 Antisense GGCAGCATTTATTACCCCATT
PECAM1 CD31F Sense ATTGCAGTGGTTATCATCGGAGT
CD31R Antisense CTCGTTGTTGGAGTTCAGAAGTGG
VWF vWF F Sense CGGCTTGCACCATTCAGCTA
vWF R Antisense TGCAGAAGTGAGTATCACAGCCATC
Exon12–20 12 Sense GCCCAATGATCTGCTTGATT
20 Antisense TTGGTTGCGTCATTACAGGA
PCR primers used for screening splice variants, cloning, qPCR and sequencing.
doi:10.1371/journal.pone.0091242.t001
PICALM and Alzheimer’s Disease
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To elucidate the impact of the primary AD-associated SNP
rs3851179 on PICALM, we chose a three-tiered approach. First,
we evaluated whether a non-synonymous PICALM SNP was in
linkage disequilibrium with rs3851179. The rs3851179 minor
allele frequency in European Americans is 35%. According to the
Exome Variant Server (http://evs.gs.washington.edu/EVS/),
there are no non-synonymous PICALM SNPs with a minor allele
frequency above 0.2% [21]. Hence, the rs3851179 association
with AD is not likely to be explained by a non-synonymous
PICALM SNP.
The second tier of our approach to elucidate SNP action was to
evaluate the extent that PICALM expression correlated with
rs3851179 genotype and/or AD status. To this end, total PICALM
expression was quantified in 52 brain samples by using qPCR and
primers corresponding to sequences within exons 9 and 10 which
are constitutively present (see below). PICALM copy number was
normalized to the geometric mean of two housekeeping genes,
RPL32 and eIF4H [13,14]. Inspection of the results supports that
total PICALM expression correlated positively with microvessel
mRNA expression (Figure 2A). To evaluate the statistical
correlation between PICALM expression and relevant indices, we
analyzed PICALM expression relative to AD status, rs3851179
genotype, and several cell-type specific mRNAs. Linear regression
analysis found an overall significant model (adjusted R2 = 0.46)
with a significant correlation between PICALM and rs3851179 as
well as cell type markers but not AD (Table 2). Rs3851179, GFAP
and microvessel mRNA correlated positively with total PICALM
expression, whereas SYP showed negative correlation. The AD-
protective, minor rs3851179A allele was associated with increased
total PICALM expression.
The third tier of our approach to determine possible SNP
function was to evaluate the extent that a PICALM splice variant
was associated with rs3851179 genotype and/or AD status. We
began by identifying PICALM splice variants present in human
brain. PCR was performed by using a series of primer pairs that
flank PICALM internal exons, e.g., primers corresponding to exons
1 and 5 were used to evaluate whether exons 2, 3 or 4 were
variably spliced. This study found that multiple PICALM exons
were inefficiently spliced (Figure 3). Sequencing of the exon 1–5
amplicons found that most PICALM isoforms contained exons 2, 3
and 4 while apparently rare isoforms lacked exon 2 or exons 2–4.
Amplifying from exon 3 to exon 9, and exon 7 to exon 12 showed
that exons 5–11 were consistently present (Figure 3). This supports
the use of primers corresponding to exons 9 and 10 for qPCR for
total PICALM. Amplification reactions between exons 10–21
overall found multiple PICALM isoforms. These isoforms were not
sufficiently resolved by polyacrylamide gel electrophoresis to allow
sequencing of individual gel-purified products. To overcome this
issue, PICALM from exon 12 to exon 20 was PCR-amplified, and
the PCR products cloned and sequenced. To gain an initial
evaluation of whether rs3851179 may be associated with PICALM
splice variants, we analyzed RNA from three rs3851179 G/G and
three rs3851179 A/A homozygous individuals. This effort
revealed that exons 13, 14, 18 and 19 were inefficiently spliced.
The most common PICALM variant lacked exon 13 and contained
each of the other exons from 12 to 20 (Table 3). Other common
variants contained each exon from 12–20, or lacked exon 13 and
the initial 15 bp of exon 15, or lacked both exon 13 and 18. A
comparison of the abundance of each isoform in rs3851179G/G
versus rs3851179A/A individuals did not reveal striking differ-
ences (Table 3). Overall, we interpret these data as indicating that
multiple PICALM exons are variably spliced. Although these
isoforms were not associated with rs3851179 in this semi-
quantitative assay, their abundance warranted a more quantitative
evaluation.
For quantitation, we initially focused on exon 13 because (i) this
exon is commonly skipped and (ii) this exon encodes the DPF
peptide motif that contributes to PICALM binding to AP2 [22].
We quantified PICALM lacking exon 13 (D13-PICALM) by using
qPCR primers corresponding to sequences within exon 11 and the
exon 12- exon 14 junction (Table 1). D13-PICALM correlated well
with total PICALM expression and constituted about 40% of total
transcript (Figure 2B). D13-PICALM expression was analyzed as a
function of rs3851179, AD status, and several cell-type specific
mRNAs. The expression of D13-PICALM correlated with
rs3851179, AD status, as well as the cell-type specific mRNAs
(adjusted R2 = 0.54, Table 2). The minor rs38555179A allele and
the absence of AD correlated with increased D13-PICALM
expression.
To evaluate whether rs3851179 was associated with D13-
PICALM independently of the SNP association with total PICALM
expression, we analyzed D13-PICALM expression as a function of
rs3851179, AD status and total PICALM expression. With this
analysis, we found that D13-PICALM was associated with AD
status and total PICALM, but not rs3851179. Hence, D13-PICALM
expression is associated with rs3851179 only because total
PICALM expression is associated with rs3851179.
We next analyzed PICALM splice variants that lacked exons 18
and 19 (D18–19 PICALM), noting that the PICALM carboxyl
region that includes amino acids encoded by exon 18 and 19 is
critical for PICALM function [23]. This qPCR assay used forward
and reverse primers that recognized exon 17 and the exon 17 -
exon 20 junction, respectively (Table 1). We found that D18–19
PICALM represented 1–2% of total PICALM expression
(Figure 2C) and correlated with neuronal and astrocyte content
but not rs3851179 (Table 2).
We next quantified isoforms that lack exon 2 (D2-PICALM).
This isoform is expected to not encode a functional protein
because the loss of exon 2 introduces a codon frameshift with a
premature stop codon in exon 3. Exon 2 encodes a portion of the
ANTH domain that binds PIP2 on the plasma membrane during
the initial stage of clathrin-coated pit formation [24], We found
that D2-PICALM was typically rare, representing less than 1% of
total PICALM expression (Figure 2D). However, two samples
showed increased D2-PICALM expression, ranging as high as
3.6%. The reason underlying the higher D2-PICALM in these
individuals was unclear; these individuals both had AD, they differ
in sex (one female and one male), and had a post-mortem interval
similar to the other samples (2.4–4.0 hours). When these outlier
samples were excluded from analysis, D2-PICALM was signifi-
cantly associated with microvessel and neuronal content, as well as
AD status but not rs3851179 genotype (adjusted R2 = 0.41,
Table 2). D2-PICALM was increased in AD individuals.
Figure 1. PICALM immunohistochemistry in human brain.
Human anterior cingulate was immunostained with anti-CALM anti-
body, revealing robust microvessel labeling (bar = 100 mm).
doi:10.1371/journal.pone.0091242.g001
PICALM and Alzheimer’s Disease
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We also identified a PICALM isoform lacking exons 2–4 (D2-4
PICALM). The D2-4 PICALM isoform was also present at low
levels, with an average of 0.2860.15% (mean 6 S.E.) of total
PICALM expression (Figure 2E). Expression of D2-4 PICALM was
associated with AD but not with rs3851179 or microvessel content,
suggesting that this variant is not expressed in microvessels
(Table 2). Interestingly, Schnetz-Boutaud et al have reported that
an exon 5 SNP rs592297 is in linkage disequilibrium with
rs3851179 (D9 = 1, r2 = 0.34) and proposed that rs592297 mod-
ulates the activity of an exon splicing enhancer [25]. Therefore we
evaluated whether rs592297 was associated with D2-4 PICALM
expression. We found that rs592297 associated with the D2-4
PICALM (Figure 2F, Table 2). Hence, higher D2-4 PICALM
expression is associated with the rs592297C minor allele. The
percentage of PICALM expressed as D2-4 PICALM was quite low
but was increased from 0.2360.11% in rs592297 major allele
homozygous samples to 0.3660.17% in samples with the rs592297
minor allele (Figure 2F, p = 0.004). Although we and others have
not examined the association of this SNP with AD directly, based
on the linkage between rs592297 and rs3851179, the minor
rs592297C allele is likely to associated with increased AD risk [25].
Discussion
The primary findings of this paper are (i) multiple PICALM
isoforms are expressed in human brain, (ii) consistent with
immunohistochemistry results that PICALM is commonly found
in microvessels, expression of total PICALM and the abundant
D13-PICALM is positively correlated with the expression of
microvessel mRNAs, (iii) total PICALM expression correlates
modestly with the AD-associated SNP rs3851179, (iv) D2-4
PICALM was associated with AD status and an exon five SNP,
rs592297, which is in linkage disequilibrium with rs3851179
(r2 = 0.34). However, D2-4 PICALM was a rare isoform, suggesting
that this association is not responsible for the SNP association with
AD, and (v) two additional rare PICALM isoforms, D18-19
PICALM and D2-PICALM were variably associated with AD and
cell-specific mRNAs. Overall, we interpret our results as suggest-
ing that multiple PICALM isoforms are expressed in the brain,
and that correcting for cell-specific mRNAs allows the discern-
ment that the AD-protective allele of rs3851179 is associated with
increased PICALM expression.
Immunostaining showed abundant PICALM expression in
microvessels. Consistent with this observation, total PICALM
expression correlated with CD31 and vWF expression, genes highly
expressed in endothelial cells [17,18]. Hence, our statistical model
for PICALM expression included the geometric mean of these
microvessel mRNAs, well as SYP and GFAP. When we analyzed
PICALM expression in this fashion, PICALM expression correlated
with rs3851179 genotype. Indeed, inclusion of the expression of
these cell-type specific mRNA is the primary difference between
our study which detected an association between PICALM
expression and rs3851179 and prior studies that did not discern
this association [26,27]. The modest association that we observed
may reflect that rs3851179 is not a functional SNP but rather is in
linkage disequilibrium with SNP(s) that directly modulate PICALM
expression. Rs3851179 is unlikely to be a directly functional SNP
since its well removed from PICALM at 80 kbp upstream and does
not alter a transcription factor binding site as predicted by
ENCODE [28]. Hence, we speculate that another SNP, more
proximal to PICALM, is the functional SNP and is in moderate
linkage disequilibrium with rs3851179.
Figure 2. Quantitative analysis of PICALM isoform expression. The indicated mRNAs or isoforms was quantified by qPCR and compared
relative to the AD-associated SNP rs3851179 (A–E) or rs592297, an exon 5 SNP (F).
doi:10.1371/journal.pone.0091242.g002
PICALM and Alzheimer’s Disease
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Variation in PICALM expression associated with rs3851179
genotype may have several effects. At the cellular level, PICALM
mediates clathrin-coated-pit endocytosis; the amino-terminus of
PICALM binds phosphatidyl-inositol 4,5 bisphosphate (PIP2),
while the central portion binds adaptor protein-2 (AP-2) and the
carboxyl terminus binds clathrin [22,29]. Reducing PICALM
expression by siRNA leads to altered size and shape of the
clathrin-coated pit [22,30]. Since the AD-protective allele of
rs3851179 correlates with increased PICALM expression, we
considered several mechanisms whereby PICALM may modulate
AD risk. First, PICALM expression modulates APP metabolism in
vitro [28]. Decreased PICALM expression leads to increased APP
at the cell surface while increased PICALM expression leads to
increased APP internalization. Since APP is metabolized in a non-
amyloidogenic pathway at the cell surface but in an amyloidogenic
pathway in endosomes, the effects of PICALM on APP
localization lead to altered Ab levels: PICALM knockdown
reduces Ab while PICALM overexpression increases Ab [31].
This pathway is not consistent with our finding that the protective
rs3851179 allele increases PICALM expression. A second pathway
whereby altered PICALM may alter AD risk recognizes that
altered PICALM expression modulates cell surface proteins in a
protein-specific fashion. For example, decreased PICALM leads to
increased GluR2 which may promote excitotoxicity [32]; the
protective rs3851179 allele that increases PICALM expression
may reduce AD risk by reducing excitotoxicity. Increased
PICALM also leads to increased cell surface transferrin and
EGFR [22,30,32,33]. Consistent with a critical role for PICALM
in iron homeostasis, PICALM-deficient mice suffer from severe
anemia and poor erythroid development and, at the cellular level,
show reduced transferrin uptake; iron supplementation amelio-
rates some aspects of PICALM deletion [23]. Recognizing that
PICALM was robustly expressed in microvessels and that
PICALM expression correlated positively with microvessel
mRNAs, we speculate that increased PICALM may be AD-
protective by facilitating Ab clearance across the blood brain
barrier [34]. Overall, altered PICALM levels may modulate AD
risk by multiple mechanisms and is the subject of ongoing
investigation.
Multiple PICALM exons were spliced inefficiently in human
brain. Isoforms lacking many of these exons are likely to encode
Table 2. Multivariate Linear Regression Analysis of Total
PICALM and Isoforms.
Standardized
Beta
Coefficients p-value
Model: Total PICALM Expression (Adj r2 = 0.46)
AD Status 20.05 0.66
Rs3851179 0.298 6.961023
Microvessel mRNA 0.387 8.661024
SYP 20.455 1.261024
GFAP 0.313 0.01
Model: D13-PICALM (Adj r2 = 0.54)
AD Status 20.304 4.961023
Rs3851179 0.268 8.161023
Microvessel mRNA 0.302 4.061023
SYP 20.519 4.261026
GFAP 0.513 1.861025
Model: D18–19 PICALM (Adj r2 = 0.21)
AD Status 0.011 0.94
Rs3851179 20.036 0.78
Microvessel mRNA 0.255 0.06
SYP 20.36 8.061023
GFAP 0.312 0.03
Model: D2-PICALM (Adj r2 = 0.41)
AD Status 0.238 0.05
Rs3851179 0.084 0.46
Microvessel mRNA 0.287 0.02
SYP 20.429 1.061023
GFAP 0.24 0.06
Model: D2–4 PICALM (Adj r2 = 0.10)
AD Status 20.322 0.03
Rs3851179 0.114 0.40
Microvessel mRNA 0.002 0.99
SYP 0.233 0.10
GFAP 20.041 0.79
Model: D2–4 PICALM (Adj r2 = 0.24)
AD Status 20.245 0.08
Rs592297 0.384 4.061023
Microvessel mRNA 0.004 0.97
SYP 0.243 0.06
GFAP 0.001 0.99
Total PICALM, D13-PICALM, D18–19 PICALM, D2-PICALM, and D2-4 PICALM
expression was analyzed as a function of AD, rs3851179 and microvessel mRNA,
SYP and GFAP content by using a linear regression model. D2-4 PICALM was also
analyzed as a function of rs592297, along with AD, microvessel mRNA, SYP and
GFAP. Adj: Adjusted
doi:10.1371/journal.pone.0091242.t002
Figure 3. PICALM splice patterns in human brain. PCR amplifica-
tion across the indicated exons was performed on cDNA pooled from
AD and non-AD brain samples. The products were separated by
polyacrylamide gel electrophoresis and visualized by SYBR-Gold
fluorescence. Single PCR products from amplifications between exon
3–9 and 7–12 indicate that individual exons between 5–11 are included
with high efficiency. The presence of multiple products in other lanes
represents inefficiently spliced exons as confirmed in Table 3.
doi:10.1371/journal.pone.0091242.g003
PICALM and Alzheimer’s Disease
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PICALM with altered function. Isoforms lacking exon 13 were
especially common. Since a critical AP-2 binding DPF peptide
motif is encoded by exon 13, the loss of exon 13 is expected to
reduce AP-2 binding [22]. Loss of this DPF motif may be
compensated by the DIF and/or FESVF motifs encoded within
exons 12 and 14, respectively [22]. Isoforms lacking exons 13 and
14 were also detected that would lack both the DPF and FESVF
motifs and would be expected to have particularly low AP-2
binding. Rare isoforms also showed an absence of exons 2 or 2–4.
Since exon 2 is 143 bp, isoforms lacking exon 2 undergo a codon
frameshift such that D2-PICALM and D2-4-PICALM are predicted
to encode only an amino terminal PICALM fragment. Since the
exon 5 SNP, rs592297, was associated with exon 2 splicing, we
sought to evaluate whether this SNP was associated with AD.
Although rs592297 was not available in data from Naj et al,
rs1237230 is highly linked with rs592297 (r2 = 0.95 in Europeans,
(http://www.broadinstitute.org/mpg/snap/ldsearch.php) and is
present in this dataset. Rs1237230 was modestly associated with
AD (p = 0.018), relative to rs3851179 (p = 0.00015) [5]. Hence,
rs592297 does not appear to be robustly associated with AD risk
relative to the primary PICALM SNP. Although rs592297 may be
a functional SNP in modulating exon 2–4 splicing, the modest
proportion of PICALM present in this isoform may mitigate the
SNP effects on overall PICALM function.
In summary, our primary findings are that multiple PICALM
isoforms are expressed in human brain, with prominent presence
in microvessels, and that overall PICALM expression is correlated
with the AD SNP rs3851179. Rare PICALM isoforms are
associated with AD status and/or rs592297, a SNP that is in
moderate linkage disequilibrium with rs3851179. The rarity of
these isoforms and their lack of association with rs3851179 suggest
they are unlikely to contribute to AD risk. Since D13-PICALM is
the most abundant PICALM isoform, future studies of PICALM
function may wish to evaluate this isoform.
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